Theravance Biopharma (NASDAQ:TBPH) Issues Earnings Results, Misses Expectations By $0.16 EPS

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. The company had revenue of $16.87 million during the quarter, compared to analysts’ expectations of $16.11 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.23%. During the same period last year, the firm earned ($0.17) earnings per share.

Theravance Biopharma Stock Down 1.1 %

NASDAQ TBPH opened at $9.57 on Friday. The firm’s fifty day simple moving average is $8.36 and its two-hundred day simple moving average is $8.69. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $11.71.

Analysts Set New Price Targets

Several research firms have recently weighed in on TBPH. TD Cowen decreased their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Leerink Partners lowered Theravance Biopharma from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Monday, September 16th. Leerink Partnrs lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Finally, StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $13.75.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 322,743 shares of the company’s stock, valued at approximately $2,904,687. The trade was a 1.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is currently owned by company insiders.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.